The short answer
Check with your prescriber before starting or stopping St John’s wort during alprazolam treatment. Some extracts substantially lower alprazolam exposure, while a low-hyperforin product had little effect in another study.
What this answer covers
Oral Hypericum perforatum extracts; hyperforin content and repeated exposure matter.
- Supplement or preparation
- Hypericum perforatum
- Medication ingredient
- alprazolam
What the direct study showed
After two weeks of one St John’s wort regimen, alprazolam exposure fell by about half and the drug cleared faster. This is direct evidence of altered alprazolam handling, though treatment failure was not measured.
Why the extract matters
A randomized study of a low-hyperforin extract found no clinically relevant alprazolam exposure change. The difference means that findings for one extract cannot be assumed for every St John’s wort product.
Plan starting or stopping
Show the prescriber the extract and dose before changing it. Enzyme effects are not solved by a proven few-hour dosing gap, and you should not increase alprazolam yourself if symptoms worsen.
Keep treatment changes supervised
Follow the prescribed alprazolam plan. Do not take extra doses to counter a supplement, and do not stop regular treatment abruptly. Ask the prescriber to plan any medication or supplement changes.
Evidence and practical considerations
Absorption & effectiveness
Direct human studies support a preparation-dependent metabolism interaction and clinician review; reduced gut absorption or uniform effects across products are not established.
- Exact scope
- Oral Hypericum perforatum extracts; hyperforin content and repeated exposure matter. with Exact oral alprazolam; no blanket benzodiazepine metabolic or route transfer.
- Medication form and route
- oral; other cannabis routes only if explicitly discussed
- Timing or duration
- Exact duration and dose depend on source; single-dose and chronic use are distinguished.
What remains uncertain
- Healthy-volunteer pharmacokinetic studies, not anxiety efficacy trials. Low-hyperforin result does not establish safety of an uncharacterized commercial product.
Factors that may matter: preparation and plant part; dose; other medicines; baseline alertness; clinical indication.
Read the supporting source summaries
Source 1: current product label
dailymed.nlm.nih.gov · Source check Sep 10, 2026
Population: Patients prescribed oral alprazolam.
CNS depression, impaired coordination and alertness can occur; concomitant CNS depressants require caution. Dependence and withdrawal risks require individualized tapering rather than abrupt cessation. Metabolism involves CYP3A; inhibitors and inducers may alter exposure. Not the same metabolic pathway profile as oxazepam or temazepam.
How this applies: Exact RxNorm ingredient and oral formulation confirmed in original label; use exact indication and metabolic boundaries.
Does not quantify the requested botanical interaction risks, prove every herb is sedating, or establish a protective supplement interval.
Source 2: original human study
pubmed.ncbi.nlm.nih.gov · Source check Sep 10, 2026
Population: Twelve healthy volunteers in an open-label fixed-order crossover.
Alprazolam exposure fell about one-half and clearance increased; elimination half-life shortened.
How this applies: Apply only to exact medication, preparation and study exposure; comparator treatment is not co-use.
Single extract and short exposure, healthy volunteers; no anxiety-treatment failure endpoint. Does not imply reduced gut absorption or transfer to predominantly conjugated benzodiazepines.
Source 3: original human study
pubmed.ncbi.nlm.nih.gov · Source check Sep 10, 2026
Population: Healthy participants in randomized placebo-controlled studies.
Changes in probe exposures were small and judged clinically irrelevant; hyperforin levels were below quantification.
How this applies: Apply only to exact medication, preparation and study exposure; comparator treatment is not co-use.
Preparation-specific result, not permission to assume all retail products are low-hyperforin or all doses safe.
Research assessment: · Open full citations ↗
Review and change history
- Publication status
- Published research summary
- Clinical review
- Not yet recorded
| Date | Update |
|---|---|
| Article prepared | |
| Current exact claims adjudicated against captured originals and explicit comparator/co-use boundaries. | |
| Research summary published |
Article revision: 5032d4f162956f3a
This guide brings together the evidence records used by our interaction checker. Each finding retains its own preparation limits, research date, and source summaries.
Full citations require verification. Reading this answer and the source summaries does not.
Taking other supplements or medications?
Use the checker to explore your other combinations. Ask a pharmacist to review the exact products, amounts and medical conditions in your complete list.
Open the interaction checkerInformation, not medical advice. Do not change prescribed treatment based on this guide.